Navigation Links
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication
Date:12/29/2010

HORSHAM, Pa., Dec. 29, 2010 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.  REMICADE was designated orphan drug status by the FDA on November 12, 2003 for the treatment of pediatric UC.  REMICADE is currently approved for the treatment of adults with moderately to severely active UC who have not responded adequately to conventional therapy.  

The sBLA is supported by data from a pivotal Phase 3, randomized, open-label trial that assessed the safety and efficacy of induction and maintenance REMICADE treatment in pediatric patients age six through seventeen who were diagnosed with moderately to severely active UC.  Eligible patients had an inadequate response to treatment with conventional treatment with 6-mercaptopurine (6-MP), azathioprine (AZA), corticosteroids, and/or 5-aminosalicylate (5-ASA) treatments.  

"Data from the Phase 3 trial support the efficacy of REMICADE in inducing clinical response, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in pediatric patients with ulcerative colitis, an orphan disease that is in need of treatment options," said Jerome A. Boscia, M.D., Senior Vice President, Clinical R&D, Centocor Research & Development, Inc.  "We are pleased to work with the FDA as we seek approval of REMICADE for the treatment of this very challenging disease."

About Ulcerative Colitis (UC)

UC, a chronic inflammatory bowel disease affecting nearly 500,000 people in the U.S., is marked by the inflammation and ulceration of the colonic mucosa, or innermost lining, which may lead
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
3. Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI® Label to Include Inhibition of Structural Damage in Treatment of Psoriatic Arthritis
4. Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
5. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
6. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
7. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
8. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
9. ORTHO EVRA(R) Prescribing Information Updated
10. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
11. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... CLEVELAND , May 22, 2013 /PRNewswire/ ... Software,s enterprise content management (ECM) ... Meditech,s Hospital Information System .  These organizations ... IT system and will use OnBase to ... corporate initiatives.   (Logo:  ...
(Date:5/22/2013)... 2013 Z-Medica, a leading developer and marketer ... first-ever line of products designed to meet the unique ... ® EMS 4x4 Dressing, QuikClot ® EMS ... Gauze™, all custom-designed to help responders stop bleeding fast ... to a hospital or trauma center. The line includes ...
(Date:5/22/2013)... May 22, 2013 Hemoglobin A1C levels ... with Type 2 diabetes, while modest improvements in ... outcomes and can lead to substantial healthcare cost ... International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ... studies, sponsored by Valeritas, makers of the V-Go ...
Breaking Medicine Technology:Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 According ... is an autoimmune disorder effecting up to 3 million ... causing damage to the small intestine and mal-absorption of ... such as diarrhea, constipation, weight loss and vitamin deficiency, ... diet. While there are many gluten-free foods that celiac ...
(Date:5/22/2013)... research shows that craving drugs such as nicotine ... brain that are implicated in determining the value ... Dr. Alain Dagher, from McGill University, suggests ... underlie addiction. These results were presented at the ... the Canadian Association for Neuroscience - Association Canadienne ...
(Date:5/22/2013)... (HealthDay News) -- Roughly four in 10 uninsured patients ... (COPD) actually do not have the lung disease, a ... were made based on an evaluation of symptoms, rather ... test known as spirometry, which shows how well a ... air they can exhale and how long that takes. ...
(Date:5/22/2013)... Mathews from the University of Melbourne said this small ... undoubted benefits from CT scans in diagnosing and monitoring ... British Medical Journal today and involved researchers ... the International Agency for Research on Cancer in Lyon, ... very useful in providing detailed three dimensional pictures to ...
(Date:5/22/2013)... King of Prussia, PA (PRWEB) May 22, 2013 ... is proud to announce its participation in the Greater Philadelphia ... experienced cyclists and recreational riders who are passionate about stopping ... affects more than 25 million Americans. , The Tour ... Ambler Campus, located at 580 Meetinghouse Road in Ambler, 30 ...
Breaking Medicine News(10 mins):Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 3Health News:Addiction as a disorder of decision-making 2Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Small increase in cancer risk following CT scans in childhood and adolescence 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3
... tripled its customer,base in 2008 and now serves more ... part because of economic uncertainty. Vendormate captures,credentials, and ... chain,interruptions. , "With the global ... anxious about their supply chain," said Andy,Monin, Vendormate president ...
... Bureau Chief Lydia Parnes -PALO ALTO, Calif., Jan. 13 ... of legal services to technology, life sciences, and growth ... the firm as a new partner in March. The ... at the Federal Trade Commission (FTC), Parnes is a ...
... Study will begin recruiting volunteers to take part in its comprehensive study ... a briefing, NIH officials announced that the first phase of recruitment for ... York. , ... Washington, DC (PRWEB) January 13, 2009 ...
... BoxTone(R) Inc., the expert in mobile user management, today announced it ... new purchases of its market-leading software solution to manage, monitor and ... ... January 13, 2009 -- BoxTone(R) Inc., the expert in mobile user ...
... PRINCETON, N.J., Jan. 13 Medarex, Inc. (Nasdaq: ... of the company,s strong science-base and strategy for ... provided were recent highlights of Medarex,s record of ... outlook for product pipeline milestones in 2009, underscoring ...
... lost substantially fewer days of work and worked fewer ... the Feb. 1 issue of Clinical Infectious Diseases ... drug resistance among this year,s flu strains, the study ... The burden of influenza-like illnesses during the flu season ...
Cached Medicine News:Health News:Economic Uncertainty Fuels Vendormate Growth in 2008 2Health News:Wilson Sonsini Goodrich & Rosati Expands Consumer Regulatory Practice 2Health News:National Children's Study Begins Recruiting Volunteers 2Health News:National Children's Study Begins Recruiting Volunteers 3Health News:National Children's Study Begins Recruiting Volunteers 4Health News:National Children's Study Begins Recruiting Volunteers 5Health News:BoxTone Presents Mobile Industry with Timely Money Back Software Guarantee for Managing Enterprise BlackBerry Platform 2Health News:BoxTone Presents Mobile Industry with Timely Money Back Software Guarantee for Managing Enterprise BlackBerry Platform 3Health News:BoxTone Presents Mobile Industry with Timely Money Back Software Guarantee for Managing Enterprise BlackBerry Platform 4Health News:Medarex Reviews Recent Highlights and Outlook for 2009 2Health News:Medarex Reviews Recent Highlights and Outlook for 2009 3Health News:Study shows workplace benefits of influenza vaccination in 50-64 year olds 2
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
For the direct, colorimetric determination of calcium in human serum or urine. Linearity: 20 mg/dl....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in human serum....
Medicine Products: